About the study
This Phase 2 study tested three doses of BI 1819479, an investigational oral medicine, against placebo in people with idiopathic pulmonary fibrosis (IPF). The main measure was how quickly lung function (forced vital capacity) declined over up to one year. Participants could join whether or not they were taking nintedanib or pirfenidone.
Who took part
The study enrolled people who:
- Were 40 years of age or older
- Had idiopathic pulmonary fibrosis (IPF)
- Were either on stable nintedanib or pirfenidone or not taking either
Status at Veritas
This study has been completed. It is no longer enrolling, and it is listed here as part of Veritas Clinical Research's track record as a research site.
Learn more
The full study record, including all eligibility criteria and outcome measures, is on ClinicalTrials.gov (NCT06335303).